Greenleaf Trust’s AbbVie ABBV Stock Holding History

Greenleaf Trust’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.3M	Buy	60,700 +962	+2%	+$207K	0.15%	50
2026 Q1	$13M	Sell	59,738 -931	-2%	-$207K	0.13%	52
2025 Q4	$13.9M	Sell	60,669 -4,032	-6%	-$918K	0.13%	55
2025 Q3	$15M	Sell	64,701 -28,666	-31%	-$5.84M	0.14%	51
2025 Q2	$17.3M	Sell	93,367 -13,928	-13%	-$2.59M	0.15%	43
2025 Q1	$22.5M	Sell	107,295 -3,237	-3%	-$629K	0.21%	30
2024 Q4	$19.6M	Buy	110,532 +5,991	+6%	+$1.1M	0.18%	38
2024 Q3	$20.6M	Buy	104,541 +4,011	+4%	+$749K	0.18%	37
2024 Q2	$17.2M	Buy	100,530 +3,806	+4%	+$630K	0.16%	41
2024 Q1	$17.6M	Buy	96,724 +940	+1%	+$162K	0.16%	41
2023 Q4	$14.8M	Buy	95,784 +10,073	+12%	+$1.47M	0.16%	46
2023 Q3	$12.8M	Buy	85,711 +1,144	+1%	+$168K	0.15%	45
2023 Q2	$11.4M	Sell	84,567 -830	-1%	-$122K	0.12%	50
2023 Q1	$13.6M	Buy	85,397 +6,334	+8%	+$968K	0.15%	43
2022 Q4	$12.8M	Sell	79,063 -40,496	-34%	-$6.21M	0.16%	46
2022 Q3	$16M	Buy	119,559 +50,904	+74%	+$7.3M	0.24%	33
2022 Q2	$10.5M	Buy	68,655 +13,604	+25%	+$2.08M	0.16%	39
2022 Q1	$8.92M	Sell	55,051 -3,974	-7%	-$577K	0.11%	48
2021 Q4	$7.99M	Buy	59,025 +8,633	+17%	+$1.02M	0.09%	54
2021 Q3	$5.44M	Sell	50,392 -1,057	-2%	-$121K	0.07%	64
2021 Q2	$5.79M	Buy	51,449 +4,055	+9%	+$457K	0.07%	61
2021 Q1	$5.13M	Buy	47,394 +1,989	+4%	+$213K	0.07%	67
2020 Q4	$4.87M	Buy	45,405 +3,908	+9%	+$376K	0.06%	65
2020 Q3	$3.63M	Buy	41,497 +2,939	+8%	+$277K	0.06%	70
2020 Q2	$3.79M	Buy	38,558 +4,966	+15%	+$437K	0.07%	66
2020 Q1	$2.56M	Sell	33,592 -165	-0.5%	-$14.1K	0.05%	76
2019 Q4	$2.99M	Buy	33,757 +3,085	+10%	+$256K	0.05%	78
2019 Q3	$2.32M	Sell	30,672 -5,507	-15%	-$378K	0.04%	91
2019 Q2	$2.63M	Buy	36,179 +2,708	+8%	+$213K	0.04%	84
2019 Q1	$2.7M	Sell	33,471 -5,359	-14%	-$438K	0.04%	75
2018 Q4	$3.58M	Buy	38,830 +4,324	+13%	+$380K	0.07%	60
2018 Q3	$3.26M	Sell	34,506 -2,680	-7%	-$254K	0.06%	73
2018 Q2	$3.44M	Buy	37,186 +3,970	+12%	+$388K	0.07%	67
2018 Q1	$3.14M	Sell	33,216 -2,742	-8%	-$301K	0.06%	73
2017 Q4	$3.48M	Sell	35,958 -1,482	-4%	-$140K	0.07%	68
2017 Q3	$3.33M	Buy	37,440 +3,512	+10%	+$267K	0.07%	69
2017 Q2	$2.46M	Sell	33,928 -327	-1%	-$22K	0.06%	79
2017 Q1	$2.23M	Sell	34,255 -2,533	-7%	-$159K	0.05%	73
2016 Q4	$2.3M	Buy	36,788 +1,078	+3%	+$65.8K	0.06%	75
2016 Q3	$2.25M	Buy	35,710 +2,512	+8%	+$163K	0.06%	70
2016 Q2	$2.06M	Sell	33,198 -1,895	-5%	-$115K	0.05%	66
2016 Q1	$2M	Sell	35,093 -5,390	-13%	-$300K	0.05%	65
2015 Q4	$2.4M	Sell	40,483 -5,305	-12%	-$306K	0.07%	57
2015 Q3	$2.49M	Buy	45,788 +3,858	+9%	+$251K	0.07%	39
2015 Q2	$2.82M	Buy	41,930 +10,075	+32%	+$658K	0.08%	38
2015 Q1	$1.86M	Buy	31,855 +844	+3%	+$51K	0.06%	51
2014 Q4	$2.03M	Sell	31,011 -170	-0.5%	-$10.7K	0.06%	49
2014 Q3	$1.8M	Sell	31,181 -346	-1%	-$19.2K	0.06%	57
2014 Q2	$1.78M	Sell	31,527 -1,234	-4%	-$64.7K	0.06%	60
2014 Q1	$1.68M	Sell	32,761 -1,878	-5%	-$94.9K	0.05%	58
2013 Q4	$1.83M	Sell	34,639 -2,149	-6%	-$106K	0.06%	54
2013 Q3	$1.65M	Sell	36,788 -1,250	-3%	-$55.4K	0.06%	51
2013 Q2	$1.57M	Buy	+38,038	New	+$1.66M	0.06%	56

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return

Greenleaf Trust's ABBV Position: Q2 2026 in Review

Greenleaf Trust increased its AbbVie (ABBV) stake by 1.6% in Q2 2026, buying an estimated $207K and bringing the position to 60,700 shares worth $15.3M. The position accounts for 0.15% of the portfolio, ranked #50.

Greenleaf Trust first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $22.5M in Q1 2025. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Greenleaf Trust held 60,700 shares of AbbVie worth $15.3M as of Q2 2026.
Greenleaf Trust bought 962 AbbVie shares in Q2 2026, an estimated $207K.
AbbVie made up 0.15% of Greenleaf Trust's portfolio in Q2 2026, its #50 holding.
Greenleaf Trust first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Greenleaf Trust's AbbVie position peaked at $22.5M in Q1 2025.
1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.